SPHRF - Starpharma's DEP Delivery Technology Edge Explained In AstraZeneca's Bcl-2/Bcl-xL Drug AZD0466

A lot of small molecule anticancer drugs have significant downsides due to poor solubility (requiring detergent additives that are toxic) and serious side effects (due to the need for high dosing to make an effective dose). Starpharma's (OCTQX:OTCQX:SPHRY) dendrimer delivery technology ((DEP)) is showing promise as a generic solution to these disadvantages of many small molecule cancer drugs. Until now, the DEP technology has not made an impact, although Starpharma is building an impressive portfolio in Phase II trials of resurrected old cancer drugs coupled with DEP to provide a new lease of